Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.22 (market cap $26.68B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.8× iShares 1 3 Year Treasury Bond ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 63 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SHY | VRTX | |
|---|---|---|
Market Cap | $26.68B | $127.55B |
Volume | 4,077,691 | 1,487,944 |
Sector | Fixed Income | Health |
52-Week High | $83.18 | $557.96 |
52-Week Low | $81.05 | $407.37 |
Typical Hold Time | 63 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY, a US stock, trades at $81.16, up 0.04% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The stock faces resistance and support near $81. Recent corporate actions include dividend payments, with the latest at $0.24 per share. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook for SHY is cautious due to bearish technical signals and a lack of current fundamental data. Investment opportunities may arise from dividend income, but risks include market volatility and reliance on broader economic conditions. Investors should seek updated financials for a complete assessment.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
